Conservationists call for urgent phaseout of keeping great apes in zoos
Wildlife charity the Born Free Foundation is urging members of the public not to visit attractions that keep animals such as gorillas, chimpanzees, bonobos and orangutans in captivity.
In a report released on Thursday, the charity said more than 1,500 great apes are held in zoos across Europe, and of these, more than 300 are found in 21 establishments across the UK.
The paper explores scientific literature, decades of observation and case studies that demonstrate the impact of keeping great apes in these environments, arguing that zoos will never meet the animals' complex physical, emotional and social needs.
Great apes can suffer from abnormal stereotypic behaviours, chronic stress, obesity, heart disease and poor mental health in zoos, the report says.
It also warns of the dangers posed to the animals breeding in zoos, such as traumatic births, high rates of stillbirths, maternal rejection and instances of infanticide.
And zoo guidelines have been found to recommend treating great apes with antidepressants to alleviate anxiety caused by living in groupings and enclosures far removed from their natural habitats, according to the findings.
Born Free criticised claims that keeping and breeding great apes in captivity is important for conservation efforts.
The charity argues that zoo-bred species are genetically and behaviourally unsuitable for release into the wild and would pose serious risks to wild populations.
The plea comes after the release of the UK Government's revised standards of modern zoo practice, which are set to take effect in May 2027.
Born Free has questioned whether any zoo will be able to meet the new great ape welfare benchmarks in full if they are implemented effectively.
In its report, the charity ultimately calls on governments, regulators, zoo associations and campaigners to work together to humanely phase out the practice across the world.
Dame Virginia McKenna, Born Free's co-founder, said: 'When I see a great ape looking at me from behind the bars or reinforced glass in a zoo, something in me falters.
'These intelligent, feeling beings do not belong in cages.'
Will Travers, Born Free's co-founder and executive president, said: 'Wild great apes and the places they live in around the world are crying out for help.
'Treating them as living commodities, to be stared at rather than admired and celebrated, shows us that, while humans may dominate this planet of the apes, we know the price of everything but the value of nothing.'
Broadcaster and naturalist Chris Packham called the report 'a distressing catalogue of wrongs wrought upon our closest genetic kin'.
'All the evidence to prove radical change is now imperative is here,' he said.
Ian Redmond, the world-renowned great ape expert, said: 'Having had the privilege of spending time with great apes in their natural habitat, where they take their own decisions in life, I find it increasingly uncomfortable seeing their lives in captivity.
'The zoo industry and the Government must take note of changing public attitudes and, based on scientific evidence of ape cognition and ecology, heed the recommendations in Born Free's new report.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
33 minutes ago
- Washington Post
Ozzy Osbourne died of a heart attack, report says, citing death certificate
LONDON — Ozzy Osbourne died of a heart attack and had coronary artery disease in addition to suffering from Parkinson's disease for years, his death certificate said. The singer had suffered from coronary artery disease as well as Parkinson's, according to the certificate filed at a register office in London and obtained by The New York Times on Tuesday. Osbourne died on July 22 at 76 .
Yahoo
an hour ago
- Yahoo
Prince Harry and others criticised by charity watchdog for letting ‘damaging' Sentebale dispute play out in public
A watchdog has cleared Prince Harry of 'over-reach' at the charity he co-founded – but says a string of failures amounted to mismanagement in its administration. Regulator the Charity Commission, which investigated Sentebale for four months, has condemned 'all parties to the dispute for allowing it to play out publicly'. The commission also says the then trustees' failure to resolve disputes internally severely affected the charity's reputation and risked undermining public trust in charities more generally. Pointing to 'a lack of clarity around role descriptions and internal policies' as the key cause for weaknesses in the management, the watchdog says the confusion inflamed tensions, which culminated in a row and mass resignations of trustees and both founding patrons, the commission found. In March, Prince Harry and Prince Seeiso of Lesotho, the co-founder, quit as patrons, saying the move was in support of the trustees – who also resigned – in a dispute with chairwoman Sophie Chandauka. 'It is devastating that the relationship between the charity's trustees and the chair of the board broke down beyond repair, creating an untenable situation,' the princes said at the time. Dr Chandauka said she had reported Sentebale's trustees to the Charity Commission and had taken legal steps to prevent her removal. She also made claims of misconduct. Prince Seeiso and Prince Harry founded the organisation in 2006 in honour of Harry's mother, Diana, to help young people and children in southern Africa, particularly those with HIV and Aids. The watchdog said the row began after 2023, when Sentebale's then trustees tried to implement a new fundraising strategy in the United States. A serious dispute then emerged between Dr Chandauka, some trustees and the Duke of Sussex. Members of the regulator said that after conducting interviews and reviewing evidence, they found the delegation of certain powers to the chair, including consideration of an executive chair role, was a 'confusing, convoluted and poorly governed' process, with a lack of clearly defined delegations. The watchdog said the then trustees failed to have proper processes and policies to investigate internal complaints. 'More generally, a lack of clear policies contributed to the failure to resolve disputes,' they concluded. And the commission said public statements made to the media and criticism made in television interviews, did not serve the charity's best interests. It found no evidence of widespread or systemic bullying or harassment, including misogyny or racism, but acknowledged 'the strong perception of ill treatment felt by a number of parties to the dispute and the impact this may have had on them personally'. Nor was there evidence of 'over-reach' by either the chair or the Duke of Sussex, it said. But the regulator concluded: 'The failure to clarify delegations within the charity to the chair, and the failure to have proper processes for internal complaints, both amount to mismanagement in the administration of the charity.' The commission has issued Sentebale with a regulatory action plan, saying the charity should have a clearly defined patron role set out in writing. The plan also includes improving complaints and whistleblowing procedures. The watchdog said all the charity's then trustees contributed to a missed opportunity to resolve issues that led to the dispute. Financial difficulties following the Covid-19 pandemic contributed to tensions, it added. David Holdsworth, chief executive of the Charity Commission, said: 'Sentebale's problems played out in the public eye, enabling a damaging dispute to harm the charity's reputation, risk overshadowing its many achievements, and jeopardising the charity's ability to deliver for the very beneficiaries it was created to serve.'
Yahoo
an hour ago
- Yahoo
Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management
Pipeline led by a new proprietary oral small molecule GLP-1 agonist and six additional innovative programs targeting the GIP, Amylin and Apelin receptors, aiming to transform treatment landscape Designed to address emerging areas of patient need, including long-term weight management, co-morbid metabolic disorders, and muscle preservation during weight loss Tokyo, Japan and Cambridge, UK, 6 August 2025 – Nxera Pharma Co., Ltd. ('Nxera'; TSE: 4565) a technology-powered biopharmaceutical company, today announces the launch of a broad new pipeline strategically focused on advancing next-generation therapies for obesity and associated metabolic disorders. Independent to the productive drug discovery collaborations with Pfizer and Eli Lilly, Nxera has established, expanded and accelerated drug discovery efforts of its own proprietary pipeline across a broad range of validated GPCR targets in these major disorders. Chris Cargill, President and CEO of Nxera, commented: 'Nxera scientists were among the pioneers in elucidating the structure of the GLP-1 receptor and other key receptors being targeted, giving us a clear advantage in developing potentially best-in-class next generation drug candidates. For the past 12 months, Nxera scientists have been advancing a broad metabolic disease pipeline to capitalize independently on our differentiated science. Today, we reveal the addition of these programs to our discovery portfolio, and are confident in achieving significant progress over the mid-term, delivering clear value for shareholders and patients in the rapidly expanding obesity market, projected to exceed US$100 billion annually in global sales.' Central to Nxera's pipeline is its new, wholly owned oral small molecule GLP-1 agonist program, focussed on differentiated chemistry, which is distinct, independent and developed separately from Pfizer's PF-06954522, allowing Nxera full control to drive rapid progress. Complementing this program, Nxera is simultaneously accelerating the advancement of an additional six established GPCR-targeted programs focused on obesity and chronic weight management: Three small molecule agonist programs (GIP, Apelin, Amylin) One small molecule antagonist program (GIP) Two long-acting programs (targets undisclosed) Nxera's pipeline leverages its proprietary NxWave™ GPCR-focused structure-based design platform to rapidly identify unique, highly differentiated lead molecules with novel chemistry. This process utilizes Nxera's NxHit proprietary small molecule libraries and NxStaR proteins for DNA encoded library (DEL) screening, distinguishing these candidates from others currently in discovery and clinical development globally. Nxera's focused approach is designed to deliver highly effective therapies addressing critical patient needs: Long-term weight maintenance: Convenient, scalable oral therapies for sustained weight loss. Targeting key obesity-related co-morbidities: Enhanced outcomes in cardiovascular, renal, and liver diseases, with new therapeutic indications emerging continuously. Reducing side effects and broadening out to difficult to treat populations: Targeted treatments for elderly, post-menopausal, and sarcopenic populations. Backed by an expert team with deep experience in GPCR drug discovery, Nxera is strategically positioned to be a leader in developing the next generation of best-in-class obesity and metabolic therapies. Nxera maintains its strong commitment to other key therapeutic areas including neurology, gastroenterology, and immunology, continuing to leverage the NxWave™ platform's proven capabilities in these domains. Separately, Nxera notes that Pfizer yesterday discontinued development of its Phase 1 candidate PF-06954522, a separate small molecule GLP-1 agonist, which was discovered under a strategic drug discovery collaboration with Nxera. This discontinuation by Pfizer was due to a portfolio decision and not because of any adverse safety findings. Nxera intends to enter discussions with Pfizer regarding potential opportunities to advance GLP-1 molecules discovered by Pfizer under the collaboration. Nxera will announce its earnings results and present operational highlights for Q2 2025 on Friday, 8 August 2025. –END– About Nxera PharmaNxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. We have built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high value, large and growing market and those in the broader APAC region. Behind that, and powered by our unique NxWave™ discovery platform, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline of potentially first- and best-in-class candidates is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across obesity and metabolic disorders, neurology/neuropsychiatry and immunology and inflammation. Nxera employs approximately 400 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma Enquiries: Nxera – Media and Investor RelationsShinya Tsuzuki, VP, Head of Investor RelationsShinichiro Nishishita, VP Investor Relations, Head of Regulatory DisclosuresMaya Bennison, Communications Manager+81 (0)3 5962 5718 | +44 (0)1223 949390 |IR@ MEDiSTRAVA (for International Media)Mark Swallow, Frazer Hall, Erica Hollingsworth+44 (0)203 928 6900 | Nxera@ Forward-looking statementsThis press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group's actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or in to access your portfolio
